Global Custom Market Research Reports Provider Company

phone

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 38
  • Category: Pharmaceuticals
  • Country: Global
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2017

Summary

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Cathepsin K or CTSK is an enzyme encoded by CTSK gene. It is closely involved in osteoclastic bone resorption and participates partially in the disorder of bone remodeling. It plays an important role in extracellular matrix degradation. The enzyme is ability to catabolize elastin, collagen, and gelatin allow it to break down bone and cartilage.

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 3 and 2 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Immunology, Oncology, Central Nervous System, Infectious Disease and Metabolic Disorders which include indications Osteoarthritis, Rheumatoid Arthritis, Bone Cancer, Bone Metastasis, Chagas Disease (American Trypanosomiasis), Neuropathic Pain and Osteoporosis.

The latest report Cathepsin K - Pipeline Review, H2 2017, outlays comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)
- The report reviews Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Publisher Name : Global Markets Direct

Introduction
Global Markets Direct Report Coverage
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Overview
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Companies Involved in Therapeutics Development
Amura Holdings Ltd
Medivir AB
Sanofi
Virobay Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Drug Profiles
AM-3701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-3876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIV-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CTSK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Dormant Products
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Discontinued Products
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Product Development Milestones
Featured News & Press Releases
Jun 09, 2017: Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation to "Go Ahead"
Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data enables trial continuation without any modifications
Dec 08, 2016: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues Without any Modifications
Oct 27, 2016: MIV-711 osteoarthritis program: Enrollment in the phase IIa study is complete and independent safety review committee again recommends Go Ahead
Sep 23, 2016: Medivir: MIV-711 Osteoarthritis Trial: Recommendation to Go Ahead Based on Independent Review of Safety Data, and First Patient Enrolled in Extension Study
Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders
May 21, 2013: Medivir Presents Positive Results From Phase Ia Study With MIV-711 For Treatment Of Skeletal Disorders At 2013 ECTS Annual Meeting
Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders
May 28, 2012: Medivir Initiates Phase I Clinical Trial Of MIV-711 For Treatment Of Bone Disorders
Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711
Sep 16, 2009: Medivir Presented Its Cathepsin K Program at the Ongoing 31st Asbmr Meeting in Denver, USA
Sep 01, 2009: Medivir Broadens Its Bone Disease Portfolio By Designating One Further Candidate Drug (CD), MIV-711
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Amura Holdings Ltd, H2 2017
Pipeline by Medivir AB, H2 2017
Pipeline by Sanofi, H2 2017
Pipeline by Virobay Inc, H2 2017
Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017

List Of Figures


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2017 Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or

View Report

Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports